Aster DM Quality Care Ltd (ASTERDM) Q1 FY27 Earnings Call: Revenue Up 20% YoY, Guides 24-25% EBITDA Margin

Aster DM Quality Care Ltd held its Q1 FY27 earnings call on August 05, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Strong Post-Merger Start; Revenue +20% YoY

• Rs.2,597 Cr pro forma revenue — Q1 FY 2026-2027 revenue grew 20% YoY; EBITDA of Rs.576 Cr (+30% YoY) with margin of 22.2% (+170 bps).
• Aster standalone revenue Rs.1,311 Cr — up 22% YoY (vs. Rs.1,078 Cr in Q1 FY 2025-2026), with operating EBITDA of Rs.277 Cr (+29% YoY) and margin of 21.1% (+117 bps).
• Normalized PAT grew 39% YoY to ~Rs.125 Cr — excludes Rs.114 Cr exceptional expense booked entirely for merger-related activities (one-time, non-indicative of underlying cost base).
• Quality Care platform: revenue Rs.1,287 Cr — up 19% YoY, operating EBITDA Rs.299 Cr (+32% YoY), margin 23.2% (+216 bps), occupancy 65.4% (+656 bps).
• Patient volumes exceeded 2 million — up 13% YoY; blended occupancy expanded 510 bps YoY to 64%; ROCE improved 190 bps to 22.6%.
• Core specialties drove strong clinical mix — orthopedics, neurology, and oncology each grew over 24% YoY; robotic volumes +80% YoY; joint replacements +39%; transplants +19%.
• Exceptional expense of Rs.114 Cr weighed on reported PAT, but management flagged it as merger-related and non-recurring.

Integration Top Priority; Rs.150-200 Cr Synergy Target

• Post-merger integration is the top priority for FY 2026-2027 — Varun Khanna identified synergy unlocking, operational/clinical excellence, and strategic roadmap as the three near-term priorities.
• No merger synergies yet realized in Q1 FY 2026-2027 — management confirmed that the separate entities (Aster and Quality Care) performed independently; synergies will start showing from FY 2026-2027 onwards.
• Management reaffirmed 10-15% incremental EBITDA synergy commitment — based on combined FY24 pro forma EBITDA, translating to Rs.150-200 Cr; synergies structured around a 10-point synergy wheel with major benefits from consumption leverage at scale.
• Synergies expected to annualize in FY 2027-2028 — clinical talent synergies will extend complex procedures (DBS, liver transplants) across the combined 39-hospital network, leveraging centers of excellence.
• Combined entity: 39 hospitals, ~10,800 beds — net debt of Rs.1,162 Cr (Aster net cash Rs.511 Cr; Quality Care debt Rs.1,673 Cr). Management will present on a consolidated basis going forward.
• Management declined to provide a geographical margin breakup (Aster vs. Q-cell), stating they are still iterating on how to present this data.

4,170 Beds Over 3-4 Years; 53% Brownfield

• Roadmap to add 4,170 beds over the next 3-4 years — management outlined a plan to "take total bed capacity to 15,000" beds; 53% of this expansion is brownfield, aiming for faster gestation and lower execution risk.
• ~1,200 greenfield beds planned over FY 2026-2027 and FY 2027-2028 — key projects include: Trivandrum (Aster Capital) operational in H2 FY 2026-2027 (~January 2027), Hyderabad hospital operational in April 2027, and Kozhikode (phase one, 450+ beds) operational in H2 FY 2027-2028.
• 159-bed Aster Women and Children block at Aster Whitefield commissioned in April 2026 — cancer center in Raipur to be inaugurated in mid-August FY 2026-2027.
• Brownfield expansions under way across multiple locations — Bhubaneswar, capacity additions in FY 2027-2028 at Kochi, and expansions in Nagarcoil, Banjara, Nampally, and Shifa.
• Kasaragod facility achieved EBITDA breakeven within 9 months — commissioned in October FY 2025-2026, reached breakeven by June 2026 with 2-3% EBITDA margin.
• Management declined to provide a hospital-wise bed expansion plan breakdown in the call, but Varun Khanna confirmed such data is available with brownfield/greenfield segmentation.

Kerala +25%, MVT +65%, Bangalore Hospitals Hit Record Revenue

• Kerala revenue grew 25% YoY in Q1 FY 2026-2027 — driven by 16% IP volume growth and 19% OP volume growth; excluding Kasaragod, growth was 20%. Medcity hospital clocked >Rs.100 Cr in two months.
• Karnataka hospitals (Bangalore) grew 16% in Q1 FY 2026-2027 — recovering from single-digit growth in earlier quarters; all three Bangalore hospitals (Aster CMI, Whitefield, RV) recorded highest ever revenue in June 2026. 18 doctors added in H2 FY 2025-2026 and Q1 FY 2026-2027.
• Medical Value Travel (MVT) growth reached ~65% in Q1 FY 2026-2027 — the first quarter of visible investment. Management guided MVT growth to continue in excess of 50% for FY 2026-2027, with share of business moving from low single digits to mid-single digits and eventually double digits over time.
• Mature units (73% of revenue): 19% revenue growth, 29% EBITDA growth, 30% EBITDA margin — margin expanded 230 bps YoY. Focus units (15% of revenue): 16% revenue growth, 20% EBITDA growth.
• Emerging units (new hospitals): 63% revenue growth, EBITDA surged 240% YoY — margin more than doubled to 12.4% (+640 bps). Nagarkoil profitable in 4 months, run rate ~Rs.180 Cr, EBITDA ~30%.
• Maturity categorisation targeting improvements — mature hospitals target 25%+ EBITDA; focus hospitals (teens EBITDA) seen as improvable; new hospitals reaching profitability quickly.

Targeting 24-25% EBITDA Margin; Double-Digit Growth Sustainable

• Management targets 24-25% EBITDA margin in 2-3 years post-merger — Sunil Kumar reaffirmed the broader target, citing a strong start in Q1 FY 2026-2027, with achievement expected "somewhere between FY28 to FY29".
• Management targets exit FY 2026-2027 at 24-25% EBITDA margin — though management declined to provide specific FY 2026-2027 yearly or quarterly EBITDA margin guidance.
• Double-digit (lower to mid-teen) growth sustainable for rest of FY 2026-2027 — Sunil Kumar guided 5-6% volume growth and 7-8% ARPP growth as the underlying drivers.
• Quality Care platform delivered 23.2% EBITDA margin in Q1 FY 2026-2027 — providing a strong base toward the 24-25% target, with 216 bps YoY expansion and 65.4% occupancy.
• MVT share to scale over time — management guided MVT from low single digits to mid-single digits and eventually double digits, supporting long-term margin mix.
• No specific numeric guidance for upcoming quarters was provided beyond the reaffirmed 2-3 year target and FY 2026-2027 growth trajectory.

Super-Specialty Focus, Tier 2/3 Expansion, Brand Strategy Under Development

• Three strategic approaches defined — Alisha Moopen outlined scaling super-specialty care (oncology, neurosciences, cardiac sciences, transplants), expanding geographic access to Tier 2/3 markets, and driving patient-centric innovation through digital health platforms.
• Key strategy: leverage clinical teams from main cities to expand into Tier 2/3 cities — management aims to deploy super-specialty expertise from Kochi, Trivandrum, and Bangalore across 28 cities and 9 states.
• Core specialties grew >24% each in Q1 FY 2026-2027 — robotic volumes +80% YoY, joint replacements +39%, transplants +19%. Cardiac is top two in volume in India.
• Management declined to converge brands — citing the strength of different brands in micro-markets; a company brand strategy is under development.
• No near-term plans to integrate payers into a health system model — management's focus remains on core operations and payer partnerships, not vertical payer integration.
• India operations divided into three regions under three CEOs — with a matrix structure incorporating clinical specialty verticals (oncology, cardiology, etc.). Varun Khanna noted the merged entity (QCIIL) provides additional capability to manage competitive intensity in Bangalore.
• Management cited a recent example of a general surgery team that left 8-9 months ago and rejoined 4 months ago, indicating strong brand credibility and clinical practice retention.